zika
viru
zikv
member
flavivirida
famili
becam
global
public
concern
correl
zika
viru
epidem
fetal
development
defect
includ
highli
public
case
viral
genom
made
posit
sens
singlestrand
rna
molecul
kb
contain
singl
open
read
frame
flank
untransl
viral
rna
translat
singl
polyprotein
co
posttransl
process
viral
cellular
proteas
three
major
structur
protein
capsid
premembran
envelop
involv
viral
entri
fusion
seven
nonstructur
ns
protein
involv
viral
rna
replic
transcript
assembl
evas
host
antivir
although
major
zikv
infect
asymptomat
associ
mild
febril
ill
infect
pregnanc
associ
miscarriag
sever
congenit
malform
includ
fetal
adult
zikv
primari
transmit
human
bite
infect
howev
nonvector
zikv
transmiss
occur
sexual
vertic
transmiss
infect
current
approv
vaccin
antivir
prevent
treat
zikv
infect
establish
plasmidbas
revers
genet
system
rna
virus
entail
rescu
recombin
virus
cdna
clone
contain
entir
viral
genom
plasmid
transfect
cultur
racaniello
baltimor
provid
basi
approach
sinc
numer
revers
genet
system
develop
posit
negativestrand
rna
plasmidbas
revers
genet
approach
allow
rescu
infecti
recombin
virus
transfect
one
plasmid
encod
compon
necessari
de
novo
gener
infecti
viru
particl
cultur
cell
importantli
revers
genet
techniqu
power
platform
modifi
viral
genom
provid
critic
insight
replic
pathogenesi
multipl
importantli
viral
revers
genet
approach
also
use
platform
develop
novel
effect
liveattenu
vaccin
lav
viral
infect
significantli
contribut
develop
antivir
howev
intrins
limit
vitro
recoveri
recombin
virus
use
revers
genet
approach
mostli
associ
cell
cultureadapt
mutat
might
restrict
andor
chang
phenotyp
viru
case
lav
mutat
could
lead
revers
virul
likewis
current
need
first
gener
recombin
virus
cultur
cell
rather
directli
valid
anim
model
infect
delay
studi
aim
understand
assess
viral
infect
vivo
therefor
high
signific
develop
approach
allow
recoveri
vivo
infecti
recombin
viru
cdna
infecti
clone
without
current
need
tissu
cultur
step
vivo
revers
genet
recov
viru
directli
valid
anim
model
could
overcom
concern
viru
adapt
cell
cultur
facilit
simplifi
studi
viru
develop
lav
base
attenu
form
virus
recent
describ
revers
genet
approach
zikv
base
use
bacteri
artifici
chromosom
bac
assembl
fulllength
genom
zikv
rio
grand
nort
natal
rgn
control
cytomegaloviru
cmv
immediateearli
promot
importantli
demonstr
feasibl
use
infecti
clone
gener
virul
rzikv
similar
vitro
vivo
characterist
natur
use
bac
infecti
cdna
clone
strain
pbaczikv
explor
possibl
recov
infecti
rzikv
directli
vivo
typei
interferon
ifn
receptor
defici
mous
model
zikv
pbaczikv
cdna
clone
complex
lipofectamin
pbaczikvlpf
inocul
mice
use
differ
inocul
rout
typic
use
zikv
infect
recoveri
rzikv
vivo
high
effici
observ
mice
addit
infecti
rzikv
also
recov
direct
inocul
infecti
cdna
clone
absenc
transfect
reagent
importantli
demonstr
feasibl
use
vivo
rescu
approach
bac
cdna
infecti
clone
encod
attenu
rzikv
rzikvatt
result
steril
immun
aggress
zikv
challeng
vivo
recoveri
fulli
infecti
andor
attenu
rna
virus
expand
potenti
use
revers
genet
system
open
possibl
develop
similar
approach
virus
could
innov
technolog
studi
futur
develop
lav
chen
et
al
previous
describ
method
vivo
recoveri
influenza
viru
iav
negativestrand
rna
viru
inocul
nasal
caviti
mice
cell
transfect
bacmid
contain
entir
iav
similar
approach
use
studi
potenti
reassort
differ
iav
subtyp
strain
thu
conduct
similar
studi
determin
whether
approach
valid
vivo
rescu
rzikv
fig
vero
cell
cell
triplic
transfect
pbaczikv
cdna
clone
use
lipofectamin
lpf
ratio
cdna
lpf
herein
refer
pbaczikvlpf
h
posttransfect
hpt
cell
trypsin
wash
resuspend
pb
use
inocul
mice
unless
otherwis
state
anim
studi
perform
old
mice
consist
micegroup
femal
male
fig
mice
inocul
pbaczikvlpftransfect
vero
cell
cellsmous
either
subcutan
sc
footpad
fig
top
panel
intramuscularli
im
quadricep
muscl
fig
middl
panel
intraperiton
ip
periton
caviti
fig
bottom
panel
anim
subsequ
monitor
daili
clinic
diseas
sign
includ
tremor
disorient
hind
limb
weak
sever
paralysi
data
shown
bodi
weight
loss
fig
surviv
fig
day
postinocul
dpi
independ
inocul
rout
mice
lost
weight
rapidli
start
dpi
fig
mice
show
sever
paralysi
succumb
diseas
dpi
fig
consist
effect
rzikv
blood
sampl
collect
dpi
test
viremia
fig
gener
viru
titer
order
focusform
unit
per
ml
ffuml
readili
observ
sampl
dpi
fig
agreement
morbid
mortal
data
fig
c
addit
success
rescu
rzikv
similar
male
femal
mice
fig
dpi
viru
detect
one
femal
mous
inocul
sc
fig
top
panel
mice
inocul
ip
fig
bottom
panel
notabl
viru
detect
dpi
mice
inocul
im
fig
middl
panel
intern
control
experi
similarli
transfect
vero
cell
maintain
cultur
rescu
rzikv
analyz
around
ffuml
detect
case
hpt
data
shown
confirm
function
pbaczikv
cdna
clone
use
vivo
experi
importantli
mice
inocul
vero
cell
transfect
empti
bac
plasmid
result
clinic
sign
diseas
bodi
weight
loss
death
rzikv
detect
day
postinocul
data
shown
data
demonstr
rzikv
success
rescu
vivo
inocul
vero
cell
transfect
pbaczikvlpf
mixtur
determin
whether
rzikv
could
rescu
vivo
directli
inocul
pbaczikv
cdna
clone
mice
inocul
pbaczikv
complex
lpf
ratio
dilut
optimem
final
volum
fig
three
rout
describ
evalu
group
mice
inocul
sc
show
one
femal
one
male
sign
infect
weight
loss
dpi
respect
fig
top
panel
mice
final
succumb
diseas
dpi
respect
fig
top
panel
viremia
correl
sign
infect
detect
presenc
rzikv
serum
inocul
femal
mous
dpi
male
sign
infect
delay
fig
top
panel
im
inocul
group
femal
male
mice
show
evid
sign
infect
dpi
result
rapid
weight
loss
death
dpi
fig
c
middl
panel
mice
show
viremia
dpi
except
femal
sign
infect
delay
dpi
fig
middl
panel
dpi
presenc
rzikv
detect
one
male
mous
although
viremia
prolong
dpi
notabl
mice
inocul
ip
succumb
viral
infect
rzikv
detect
sera
anim
sampl
dpi
fig
bottom
panel
gener
deliveri
vivo
pbaczikvlpf
mixtur
sign
diseas
delay
day
compar
mice
infect
delay
correl
detect
rzikv
dpi
mice
inocul
pbaczikvlpf
mixtur
intern
control
experi
vero
cell
transfect
pbaczikvlpf
mixtur
contain
plasmid
dna
use
inocul
mice
result
ffuml
rzikv
hpt
confirm
qualiti
transfect
mixtur
use
vivo
studi
data
shown
notabl
mice
inocul
empti
bac
plasmid
result
recoveri
zikv
day
postinocul
clinic
sign
diseas
bodi
weight
loss
death
observ
data
shown
data
demonstr
rzikv
success
recov
vivo
effici
inocul
periton
caviti
mice
pbaczikvlpf
mixtur
sinc
ip
inocul
effici
rout
vivo
rzikv
rescu
next
evalu
minim
amount
pbaczikvlpf
requir
effect
fig
group
mice
inocul
either
pbaczikv
cdna
complex
lpf
dna
lpf
ratio
optimem
mice
inocul
pbaczikvlpf
mixtur
lost
weight
rapidli
fig
succumb
infect
dpi
depend
pbaczikv
concentr
fig
rzikv
detect
serum
dpi
fig
anim
delay
bodi
weight
loss
one
male
inocul
two
femal
inocul
pbaczikvlpf
viru
detect
dpi
fig
hand
two
male
one
femal
inocul
pbaczikvlpf
mixtur
show
bodi
weight
loss
fig
succumb
viral
infect
fig
present
viremia
dpi
result
latter
group
suggest
pbaczikv
within
lower
limit
vivo
rescu
rzikv
fig
gener
success
vivo
rzikv
rescu
similar
male
femal
mice
find
consist
throughout
studi
furthermor
data
suggest
recoveri
rzikv
vivo
depend
concentr
pbaczikv
littl
pbaczikvlpf
mixtur
suffici
effici
rescu
rzikv
test
whether
rzikv
recov
pbaczikvlpfinocul
mice
maintain
predict
virul
properti
perform
second
round
infect
mice
sampl
rzikv
isol
one
male
one
femal
mice
previous
inocul
pbaczikvlpf
mixtur
fig
use
infect
mice
sc
rout
lethal
dose
viru
ffumous
mice
second
round
infect
lost
weight
rapidli
fig
sign
zikv
infect
diseas
mice
indistinguish
similar
studi
mice
infect
wild
type
rzikv
data
shown
die
dpi
fig
expect
high
viral
titer
detect
dpi
declin
dpi
fig
genjet
signagen
transfect
reagent
specif
formul
vivo
dna
deliveri
thu
evalu
vivo
effici
rescu
rzikv
complex
genjet
instead
lpf
addit
also
evalu
rescu
effici
inocul
mice
nake
pbaczikv
cdna
without
transfect
reagent
fig
mice
inocul
ip
solut
contain
pbaczikv
complex
genjet
ratio
dna
genjet
reagent
dilut
glucos
water
solut
pbaczikvgenjet
transfect
reagentfre
nake
pbaczikv
cdna
optimem
third
group
inocul
pbaczikvlpf
mixtur
use
control
fig
intern
control
vero
cell
transfect
vitro
mixtur
contain
plasmid
dna
viral
titer
ffuml
detect
hpt
tissu
cultur
supernat
vero
cell
transfect
lpf
genjet
respect
expect
viru
recov
vitro
without
use
transfect
reagent
transfect
empti
bac
transfect
reagent
data
shown
vivo
mice
inocul
either
pbaczikvgenjet
pbaczikvlpf
mixtur
began
lose
weight
dpi
fig
start
succumb
viral
infect
dpi
fig
agreement
morbid
mortal
observ
high
viral
titer
detect
dpi
fig
top
middl
panel
one
male
inocul
pbaczikvgenjet
mixtur
show
slight
delay
bodi
weight
loss
viremia
dpi
succumb
infect
dpi
fig
middl
panel
differ
observ
mice
group
inocul
pbaczikvgenjet
pbaczikvlpf
mixtur
surprisingli
mice
inocul
transfect
reagentfre
nake
pbaczikv
cdna
show
clear
sign
diseas
data
shown
bodi
weight
loss
fig
bottom
panel
succumb
viral
infect
fig
bottom
panel
viremia
detect
dpi
correl
diseas
progress
fig
bottom
panel
base
result
next
determin
minim
amount
transfectionreag
free
nake
pbaczikv
cdna
requir
vivo
rzikv
rescu
fig
mice
inocul
ip
either
nake
pbaczikv
cdna
optimem
rzikv
rescu
vivo
inocul
nake
pbaczikv
cdna
viru
recoveri
sexindepend
similar
effici
femal
male
mice
fig
howev
recoveri
infecti
rzikv
use
nake
pbaczikv
cdna
less
effici
use
lpf
genjet
fig
b
least
nake
pbaczikv
cdna
clone
requir
fig
top
panel
compar
pbaczikvlpf
mixtur
fig
success
recoveri
rzikv
effici
next
explor
feasibl
vivo
revers
genet
system
potenti
vaccin
platform
prevent
typic
zikv
infect
fig
toward
end
zikv
bac
cdna
clone
pbaczikvatt
carri
valin
v
alanin
substitut
posit
viral
protein
render
viru
attenu
mice
compar
wild
type
mice
inocul
ip
pbaczikvattlpf
mixtur
fig
top
panel
empti
pbac
vectorlpf
mixtur
control
fig
middl
panel
anoth
control
includ
mice
infect
sc
subleth
dose
x
vitro
gener
rzikvatt
fig
bottom
panel
expect
mice
inocul
empti
pbac
cdna
vectorlpf
neither
lost
weight
die
viru
undetect
fig
middl
panel
mice
inocul
pbaczikvattlpf
group
lost
weight
dpi
otherwis
healthi
surviv
remark
viremia
detect
pbaczikvattlpf
group
dpi
indic
success
vivo
rescu
rzikvatt
fig
top
panel
similarli
mice
infect
subleth
dose
rzikvatt
lost
weight
dpi
show
viremia
dpi
prolong
dpi
case
eventu
mice
recov
surviv
infect
fig
b
bottom
panel
observ
previous
wild
type
pbaczikv
cdna
clone
sign
diseas
viremia
delay
day
vivo
inocul
pbaczikvattlpf
mixtur
compar
direct
rzikvatt
inocul
intern
control
vero
cell
transfect
vitro
pbaczikvattlpf
use
vivo
rescu
result
ffuml
hpt
confirm
function
pbac
cdna
clone
use
vivo
experi
evalu
whether
ip
inocul
pbaczikvattlpf
mixtur
would
lead
protect
respons
zikv
mice
end
mice
inocul
empti
pbac
pbaczikvatt
complex
lpf
infect
subleth
dose
rzikvatt
describ
mice
bled
dpi
sera
collect
evalu
igg
antibodi
total
zikv
protein
elisa
fig
specif
antibodi
zikv
antigen
detect
mice
inocul
pbaczikvattlpf
sampl
empti
pbac
vectorlpfinocul
mice
importantli
level
antibodi
compar
obtain
mice
infect
subleth
dose
x
rzikvatt
fig
right
panel
evalu
zikv
neutral
antibodi
nab
focusreduct
neutral
test
frnt
vero
cell
fig
reveal
robust
nab
respons
serum
sampl
mice
inocul
pbaczikvattlpf
mixtur
sampl
mice
inocul
empti
pbac
vectorlpf
control
nab
respons
pbaczikvattlpfinocul
group
fig
middl
panel
similar
serum
sampl
mice
infect
subleth
dose
rzikvatt
fig
right
panel
given
strong
humor
respons
elicit
inocul
pbaczikvatt
next
examin
protect
level
vaccin
mice
lethal
challeng
dpi
lethal
dose
rzikv
x
mice
pbaczikvattlpfinocul
group
control
rzikvatt
group
fulli
protect
lethal
rzikv
challeng
show
sign
diseas
bodi
weight
loss
fig
viremia
level
detect
contrast
mice
inocul
empti
pbac
vectorlpf
mixtur
pb
mockinocul
succumb
viral
infect
day
postchalleng
fig
typic
clinic
sign
zikv
infect
data
shown
high
viru
titer
day
postchalleng
fig
altogeth
result
demonstr
singl
ip
inocul
pbaczikvattlpf
mixtur
safe
immunogen
provid
steril
immun
lethal
challeng
virul
rzikv
strain
revers
genet
approach
success
use
past
gener
recombin
infecti
virus
permiss
cell
importantli
revers
genet
essenti
defin
molecular
signatur
rna
virus
respons
replic
transcript
assembl
transmiss
hostviru
interact
major
caveat
current
use
revers
genet
approach
howev
vitro
cultur
system
impos
bottleneck
rna
virus
eventu
lead
select
viru
popul
adapt
grow
vitro
effect
may
imped
rescu
biolog
relev
virus
ultim
replac
alter
phenotyp
vivo
compar
wildtyp
field
isol
similar
concern
rais
gener
lav
treatment
viral
system
allow
de
novo
synthesi
rna
virus
directli
vivo
potenti
overcom
current
limit
vitro
system
includ
unwant
mutat
allow
comprehens
analysi
molecular
attribut
field
strain
anim
model
natur
host
report
expand
potenti
vivo
revers
genet
describ
show
effici
rescu
rzikv
bac
cdna
clone
pbaczikv
systemat
analyz
whether
vero
cell
transfect
pbaczikv
pbaczikvlpf
mixtur
nake
pbaczikv
without
transfect
reagent
suitabl
platform
gener
rzikv
vivo
previous
shown
intranas
inocul
cell
transfect
revers
genet
clone
iav
bacmid
dna
lead
gener
infecti
show
rout
sc
ip
im
also
suitabl
transfectionbas
inocul
vivo
revers
genet
least
rescu
rzikv
hand
develop
vivo
rescu
approach
base
direct
inocul
pbaczikv
complex
lpf
direct
inocul
either
sc
im
ip
rout
pbaczikvlpf
result
success
effici
rzikv
recoveri
ip
rout
consist
effici
dna
without
transfect
reagent
shown
effect
gene
transfer
express
follow
direct
inject
skelet
muscl
skin
vivo
first
report
ip
deliveri
express
nake
dna
regardless
inocul
rout
use
viru
produc
use
vivo
revers
genet
approach
reproduc
diseas
associ
zikv
infect
mous
model
includ
neurolog
sign
bodi
weight
loss
death
observ
zikv
infect
delay
day
pbaczikv
inocul
compar
zikvinfect
mice
explain
fact
viral
rna
transcrib
pbaczikv
cellular
rna
polymeras
ii
nucleu
transfect
cell
amplifi
cytoplasm
viral
replicas
consid
time
need
rescu
virus
use
revers
genet
cultur
cell
vivo
revers
genet
also
repres
signific
improv
time
virus
studi
anim
model
infect
rzikv
gener
vivo
inocul
conserv
infect
virul
use
infect
new
mice
import
impli
system
recapitul
bona
fide
zikv
replic
cycl
studi
suggest
vivo
zikv
rescu
depend
concentr
plasmid
viru
recov
even
absenc
transfect
reagent
albeit
lower
effici
also
repres
advantag
current
vitro
revers
genet
approach
requir
use
expens
transfect
reagent
success
recoveri
virus
cultur
cell
overal
result
demonstr
feasibl
use
vivo
revers
genet
approach
success
rescu
rzikv
vivo
methodolog
could
use
directli
test
contribut
specif
mutat
viral
genom
vivo
without
need
prior
recov
amplifi
viru
vitro
minim
potenti
mutat
associ
passag
viru
cultur
cell
overal
reduc
time
requir
studi
virus
valid
anim
model
infect
moreov
approach
could
use
rescu
rna
virus
poor
replic
properti
cultur
import
indic
studi
base
use
ifnar
mice
defici
type
ifn
respons
anim
model
infect
zikv
use
differ
rout
eg
subcutan
intraperiton
intramuscular
result
neurolog
diseas
anim
succumb
viral
infect
high
viral
load
blood
organ
liver
spleen
kidney
brain
spin
cord
consist
zikv
infect
manifest
human
contrari
infect
wt
mice
zikv
result
clinic
sign
infect
mortal
detect
viru
differ
time
postinfect
blood
organ
infect
thu
use
ifnar
immunodefici
mice
repres
best
suitabl
model
demonstr
success
rescu
recombin
zikv
use
vivo
revers
genet
studi
use
relev
anim
model
zikv
infect
current
outsid
scope
manuscript
demonstr
feasibl
use
similar
vivo
revers
genet
feasibl
gener
recombin
zikv
previou
studi
report
vitro
transcrib
hepat
c
viru
hcv
viral
v
rna
infecti
direct
inject
liver
import
technic
advanc
field
sinc
hcv
replic
effici
cell
howev
also
major
limit
includ
need
transcrib
vrna
vivo
deliveri
may
introduc
spuriou
mutat
also
limit
qualiti
quantiti
stabil
transcrib
vrna
vivo
sens
approach
recov
recombin
virus
vivo
repres
major
advanc
sinc
plasmid
dna
easier
produc
stabl
vrna
transcript
plasmid
dna
inocul
ip
allow
system
deliveri
therefor
specif
organ
inject
abl
obtain
viral
rescu
success
use
plasmid
dna
alon
combin
transfect
reagent
also
result
demonstr
im
rout
valid
vivo
dna
deliveri
also
serv
use
method
vivo
rescu
rzikv
although
ip
rout
effici
recoveri
rzikv
challeng
gold
standard
im
rout
plasmid
dna
deliveri
vivo
dna
vaccin
sever
advantag
lav
includ
stabil
howev
dna
vaccin
hamper
issu
relat
poor
immunogen
andor
need
inocul
high
amount
mg
order
gener
adequ
protect
respons
contrast
lav
shown
provid
effici
multidimension
protect
respons
stimul
humor
cellular
protect
immun
respons
major
drawback
lav
may
requir
special
cultur
system
substrat
product
coldchain
maintain
integr
abil
combin
advantag
two
system
like
one
describ
report
open
excit
possibl
greatli
improv
vaccin
vaccin
strategi
myriad
pathogen
includ
zikv
took
advantag
previous
describ
pbaczikvatt
cdna
infecti
show
rzikvatt
effici
recov
safe
vivo
turn
produc
strong
humor
respons
includ
high
level
neutral
antibodi
capabl
protect
mice
lethal
rzikv
challeng
new
vivo
viral
rescu
platform
vaccin
develop
offer
numer
advantag
compar
tradit
approach
combin
advantag
dna
vaccin
stabil
easi
product
low
manufactur
cost
limit
coldchain
requir
strength
lav
dose
spare
broad
innat
adapt
immun
respons
importantli
new
vivo
revers
genet
approach
could
extend
vaccin
develop
rna
virus
repres
concern
human
health
african
green
monkey
kidney
epitheli
vero
cell
atcc
grown
dulbecco
modifi
eagl
medium
dmem
mediatech
inc
supplement
fetal
bovin
serum
fb
mm
lglutamin
uml
penicillin
streptomycin
rzikv
wild
type
correspond
attenu
att
strain
previous
obtain
transfect
vero
cell
correspond
infecti
bac
cdna
clone
rzikvatt
contain
valin
v
alanin
substitut
posit
viral
protein
render
viru
attenu
briefli
zikv
genom
assembl
bac
plasmid
control
cmv
promot
flank
end
hepat
delta
viru
hdv
ribozym
bovin
growth
hormon
bgh
termin
polyadenyl
infecti
clone
propag
strain
e
coli
gibcobrl
bac
prepar
use
qiagen
plasmid
giga
kit
follow
manufactur
specif
vero
cell
grown
confluenc
plate
format
cellswel
triplic
transfect
zikv
bac
cdna
clone
use
lpf
invitrogen
describ
hpt
media
remov
replac
grown
media
supplement
fb
vitro
rescu
tissu
cultur
supernat
collect
day
cytopath
effect
cpe
appar
store
viru
stock
propag
vero
cell
titrat
immunofocu
assay
vero
cell
use
panflaviviru
envelop
e
protein
monoclon
antibodi
mab
bei
resourc
viral
titer
express
focusform
unit
per
ml
ffuml
ifnar
mice
jackson
laboratori
bred
maintain
anim
care
facil
univers
rochest
medic
center
urmc
mice
hous
specif
pathogenfre
condit
mous
experi
approv
univers
rochest
committe
anim
resourc
carri
complianc
recommend
guid
care
use
laboratori
anim
nation
research
fourtofiveweekold
femal
andor
male
mice
anesthet
ip
solut
ketamin
mgkg
xylazin
mgkg
inocul
footpad
subcutan
sc
quadricep
muscl
intramuscularli
im
periton
caviti
intraperiton
ip
indic
main
text
morbid
bodi
weight
loss
paralysi
mortal
monitor
day
mice
show
sever
sign
paralysi
mice
lost
initi
bodi
weight
human
euthan
follow
avma
guidelin
statist
analys
perform
use
prism
softwar
graphpad
version
mous
sera
collect
submandibular
bleed
indic
dpi
blood
maintain
room
temperatur
min
allow
clot
serum
separ
centrifug
rpm
min
immedi
store
viral
titer
determin
ffu
assay
vero
assess
level
virusspecif
antibodi
present
sera
vaccin
mice
elisa
perform
previous
briefli
elisa
plate
thermofish
coat
extract
zikvinfect
vero
cell
incub
overnight
coat
well
block
bsa
pb
incub
serial
dilut
mice
sera
start
dilut
h
follow
incub
horseradish
peroxidas
hrp
conjug
goat
antimous
igg
h
reaction
develop
tetramethylbenzidin
tmb
substrat
biolegend
min
room
temperatur
quench
n
read
nm
vmax
kinet
micropl
reader
molecular
devic
presenc
neutral
antibodi
sera
vaccin
mice
determin
frnt
previous
briefli
serial
dilut
sera
start
dilut
incub
ffu
rzikv
h
use
infect
subconflu
monolay
vero
cell
plate
min
viral
absorpt
virussera
mixtur
remov
cell
overlaid
growth
medium
contain
fb
avicel
cell
fix
h
postinfect
paraformaldehyd
prepar
immunostain
assay
use
mab
viral
plaqu
visual
use
vectastin
abc
kit
dab
hrp
substrat
vector
laboratori
inc
follow
manufactur
instruct
